Peter Lee, MD
Cardiovascular Disease · Madison, WINPI 1487605861
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,650 of the $2,287 with a category attached, or 72.1%. Heartflow, Inc. accounts for 87.3% of it on its own, with 2 other manufacturers making up the rest. 2025 is the largest year on record at $2,019, more than ten times the $69 reported in 2021.
Across 16 payments — averaging $142.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Heartflow, Inc.$2K
- Bard Peripheral Vascular, Inc.$269
- Cook Medical LLC$21
Across 6 payments — averaging $7683.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$46K
What the payments were for
- Travel & lodging$1,65072%
- Food & beverage$63828%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Heartflow, Inc. | 9 | $1,998 |
| Bard Peripheral Vascular, Inc. | 6 | $269 |
| Cook Medical LLC | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FFRct$1,870
How this compares
$2,287 in reported general payments places this provider in the 65th percentile of 322 cardiovascular disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 168 | $176,679 |
| XareltoRivaroxaban | 70 | $77,793 |
| EntrestoSacubitril/Valsartan | 22 | $30,677 |
| Metoprolol Succinate | 373 | $6,720 |
| Chlorthalidone | 258 | $4,159 |
| Bumetanide | 87 | $3,293 |
| Atorvastatin Calcium | 243 | $2,714 |
| Lisinopril | 160 | $1,499 |
| Losartan Potassium | 130 | $1,425 |
| Amiodarone Hcl | 41 | $1,323 |
| Metoprolol Tartrate | 181 | $1,308 |
| Carvedilol | 91 | $1,061 |
| Rosuvastatin Calcium | 102 | $872 |
| ClopidogrelClopidogrel Bisulfate | 62 | $759 |
| Spironolactone | 99 | $758 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Madison
- Sunil VasireddiMadison$36K
- Peter MarogilMadison$25K
- Colton ThompsonMadison$18K
- Lawrenshey CharlesMadison$15K
- Joseph LonginoMadison$8K
- David SloskyMadison$8K
- Meisam MoghbelliMadison$7K
- David KerblMadison$6K
- Subhashish AgarwalBrookfield$378K
- Lee BibloMilwaukee$280K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.